FI3452829T3 - Perm endometriumsyövän markkerina - Google Patents
Perm endometriumsyövän markkerina Download PDFInfo
- Publication number
- FI3452829T3 FI3452829T3 FIEP17713973.0T FI17713973T FI3452829T3 FI 3452829 T3 FI3452829 T3 FI 3452829T3 FI 17713973 T FI17713973 T FI 17713973T FI 3452829 T3 FI3452829 T3 FI 3452829T3
- Authority
- FI
- Finland
- Prior art keywords
- perm
- spit1
- nampt
- ldha
- mmp9
- Prior art date
Links
- 206010014733 Endometrial cancer Diseases 0.000 title claims 19
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims 19
- 239000003550 marker Substances 0.000 title claims 4
- 208000019585 progressive encephalomyelitis with rigidity and myoclonus Diseases 0.000 claims 68
- 101001090713 Homo sapiens L-lactate dehydrogenase A chain Proteins 0.000 claims 32
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims 32
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims 32
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 32
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 claims 32
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 claims 32
- 201000003914 endometrial carcinoma Diseases 0.000 claims 18
- 238000000034 method Methods 0.000 claims 15
- 239000012530 fluid Substances 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 210000004392 genitalia Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 210000001752 female genitalia Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
- G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
- G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16168328 | 2016-05-04 | ||
| PCT/EP2017/057635 WO2017190896A1 (en) | 2016-05-04 | 2017-03-30 | Mmp9 as marker of endometrial cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3452829T3 true FI3452829T3 (fi) | 2024-03-20 |
Family
ID=56096908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17713973.0T FI3452829T3 (fi) | 2016-05-04 | 2017-03-30 | Perm endometriumsyövän markkerina |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190137499A1 (enExample) |
| EP (3) | EP4610655A3 (enExample) |
| JP (3) | JP7240712B2 (enExample) |
| AU (3) | AU2017260806B9 (enExample) |
| BR (1) | BR112018072498A2 (enExample) |
| CA (2) | CA3286798A1 (enExample) |
| DK (1) | DK3452829T3 (enExample) |
| ES (1) | ES2974307T3 (enExample) |
| FI (1) | FI3452829T3 (enExample) |
| PL (1) | PL3452829T3 (enExample) |
| PT (1) | PT3452829T (enExample) |
| WO (1) | WO2017190896A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7421218B2 (ja) * | 2017-07-21 | 2024-01-24 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 子宮内膜癌のマーカとしてのａｇｒｉｎ |
| CN118556133A (zh) | 2021-07-23 | 2024-08-27 | 瓦尔德西布伦大学医院基金会研究所 | 子宫内膜癌的生物标记物 |
| CN113493838B (zh) * | 2021-09-06 | 2021-11-23 | 北京泱深生物信息技术有限公司 | 子宫内膜癌相关的标志分子及其在诊断子宫内膜癌中的应用 |
| KR102640230B1 (ko) * | 2021-09-24 | 2024-02-22 | 가천대학교 산학협력단 | C-peptide를 처리한 자궁내막 기질세포의 이동성 변화 기작을 이용한 자궁내막 관련질환의 진단 방법 및 자궁내막 관련질환 치료제의 스크리닝 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444879A (en) * | 1981-01-29 | 1984-04-24 | Science Research Center, Inc. | Immunoassay with article having support film and immunological counterpart of analyte |
| AUPO573697A0 (en) * | 1997-03-20 | 1997-04-10 | Prince Henry's Institute Of Medical Research | Diagnosis of endometrial cancer |
| US20080226554A1 (en) * | 2003-12-23 | 2008-09-18 | Mount Sinai Hospital | Methods For Detecting Markers Associated With Endometrial Disease or Phase |
| WO2008003024A2 (en) * | 2006-06-28 | 2008-01-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Method and composition for diagnosing endometrial cancer |
| WO2008049239A1 (en) * | 2006-10-27 | 2008-05-02 | Mount Sinai Hospital | Endometrial biomarkers |
| CN102549169B (zh) * | 2009-07-24 | 2016-02-24 | 吉第克生物技术有限公司 | 子宫内膜癌的标记物 |
-
2017
- 2017-03-30 FI FIEP17713973.0T patent/FI3452829T3/fi active
- 2017-03-30 PL PL17713973.0T patent/PL3452829T3/pl unknown
- 2017-03-30 CA CA3286798A patent/CA3286798A1/en active Pending
- 2017-03-30 EP EP25190526.1A patent/EP4610655A3/en active Pending
- 2017-03-30 JP JP2018557905A patent/JP7240712B2/ja active Active
- 2017-03-30 CA CA3022586A patent/CA3022586A1/en active Pending
- 2017-03-30 ES ES17713973T patent/ES2974307T3/es active Active
- 2017-03-30 EP EP23150361.6A patent/EP4180814A3/en active Pending
- 2017-03-30 EP EP17713973.0A patent/EP3452829B1/en active Active
- 2017-03-30 BR BR112018072498A patent/BR112018072498A2/pt active IP Right Grant
- 2017-03-30 PT PT177139730T patent/PT3452829T/pt unknown
- 2017-03-30 AU AU2017260806A patent/AU2017260806B9/en active Active
- 2017-03-30 DK DK17713973.0T patent/DK3452829T3/da active
- 2017-03-30 US US16/098,813 patent/US20190137499A1/en not_active Abandoned
- 2017-03-30 WO PCT/EP2017/057635 patent/WO2017190896A1/en not_active Ceased
-
2022
- 2022-11-09 US US17/984,197 patent/US20230221323A1/en not_active Abandoned
-
2023
- 2023-01-13 JP JP2023003700A patent/JP7492287B2/ja active Active
- 2023-08-02 AU AU2023210591A patent/AU2023210591B9/en active Active
-
2024
- 2024-05-10 JP JP2024077227A patent/JP2024116127A/ja active Pending
-
2025
- 2025-09-01 AU AU2025223935A patent/AU2025223935A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4180814A2 (en) | 2023-05-17 |
| JP2023040246A (ja) | 2023-03-22 |
| AU2017260806B9 (en) | 2023-07-20 |
| AU2017260806B2 (en) | 2023-06-15 |
| JP7492287B2 (ja) | 2024-05-29 |
| PL3452829T3 (pl) | 2024-05-20 |
| AU2017260806A1 (en) | 2018-12-13 |
| EP3452829B1 (en) | 2024-01-24 |
| WO2017190896A1 (en) | 2017-11-09 |
| US20190137499A1 (en) | 2019-05-09 |
| ES2974307T3 (es) | 2024-06-26 |
| EP4610655A2 (en) | 2025-09-03 |
| AU2023210591B2 (en) | 2025-06-26 |
| JP7240712B2 (ja) | 2023-03-16 |
| BR112018072498A2 (pt) | 2019-03-12 |
| EP4610655A3 (en) | 2025-12-10 |
| EP3452829A1 (en) | 2019-03-13 |
| DK3452829T3 (da) | 2024-03-25 |
| US20230221323A1 (en) | 2023-07-13 |
| CA3022586A1 (en) | 2017-11-09 |
| AU2025223935A1 (en) | 2025-09-18 |
| CA3286798A1 (en) | 2025-10-30 |
| JP2019516104A (ja) | 2019-06-13 |
| EP4180814A3 (en) | 2023-07-12 |
| AU2023210591A1 (en) | 2023-08-24 |
| AU2023210591B9 (en) | 2025-07-10 |
| JP2024116127A (ja) | 2024-08-27 |
| PT3452829T (pt) | 2024-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Granato et al. | HE4 in the differential diagnosis of ovarian masses | |
| JP2017184729A5 (enExample) | ||
| Zheng et al. | Human leukocyte antigen G is associated with esophageal squamous cell carcinoma progression and poor prognosis | |
| FI3452829T3 (fi) | Perm endometriumsyövän markkerina | |
| RU2016134839A (ru) | Биомаркер и способы для ранней диагностики болезни альцгеймера | |
| DE60129151D1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| RU2015119512A (ru) | Метилглиоксаль в качестве маркера злокачественной опухоли | |
| MX2022001087A (es) | Ergotioneina, s-metil-ergotioneina, y usos de las mismas. | |
| Benati et al. | The clinical significance of DJ‐1 and HE 4 in patients with endometrial cancer | |
| JP2008292424A (ja) | 腫瘍の検出方法 | |
| Hoorzad et al. | Evaluation of Human Epididymis Protein 4 Tumor Marker Level in the First Half of Pregnancy | |
| US20160370379A1 (en) | Blood-based biomarker for cancer | |
| Yu et al. | Clinical value of tumour specific growth factor (TSGF) and carbohydrate antigen-125 (CA-125) in carcinoma of the endometrium | |
| JP2019516104A5 (enExample) | ||
| JPWO2017122780A1 (ja) | 褥瘡発生予測マーカー及びその使用 | |
| ES2993494T3 (en) | Biomarkers for disease progression in squamous cell carcinoma | |
| CN104251906A (zh) | 一种肿瘤标志物 | |
| BR112021023247A2 (pt) | Métodos de diagnóstico e tratamento do câncer cervical | |
| Bodzek et al. | Are IgG antibodies to heat shock proteins HSP27 and HSP60 useful markers in endometrial cancer and cervical cancer? | |
| JP6363652B2 (ja) | 樹状細胞腫瘍ワクチンの適性評価方法及び生存率の予測方法 | |
| Ahrens et al. | Evaluation of YB-1 levels in patients with endometriosis | |
| Schneider et al. | Calcitonin screening in patients with thyroid nodules | |
| Eoli et al. | P11. 19. A MACROPHAGES-BASED IMMUNOTHERAPY OF SOLID TUMORS MICROENVIRONMENT: THE TEM-GBM STUDY (NCT03866109) | |
| WO2018095872A1 (en) | Gfap accumulating in stroke | |
| CN112646886A (zh) | Foxd1在侵袭性乳腺癌中的应用 |